Overview

Historical Returns (%) as of Sep 30, 2024

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund’s current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.25%.
 

Fund Facts as of Nov 30, 2024

Class A Inception 09/23/1931
Investment Objective Total return
Total Net Assets $1.6B
Minimum Investment $1000
Expense Ratio2 1.03%
CUSIP 277905808

Top 10 Holdings (%)3,4 as of Sep 30, 2024

Thermo Fisher Scientific Inc 3.00
Reinsurance Group of America Inc 2.74
Charles Schwab Corp 2.67
NextEra Energy Inc 2.65
AbbVie Inc 2.60
Micron Technology Inc 2.46
Bristol-Myers Squibb Co 2.29
American International Group Inc 2.22
Johnson Controls International plc 2.21
Cisco Systems Inc 2.21
Total 25.07
 

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.

RISK CONSIDERATIONS 

The value of investments held by the Fund may increase or decrease in response to economic, and financial events (whether real, expected or perceived) in the U.S. and global markets. The value of equity securities is sensitive to stock market volatility. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical, currency exchange rates or other conditions. The Fund is exposed to liquidity risk when trading volume, lack of a market maker or trading partner, large position size, market conditions, or legal restrictions impair its ability to sell particular investments or to sell them at advantageous market prices. The impact of the coronavirus on global markets could last for an extended period and could adversely affect the Fund’s performance. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.

See the Fund's prospectus for information related to a primary benchmark index selected (if applicable) to comply with a regulation that requires the Fund's primary benchmark to represent the overall applicable market.


Performance

Historical Returns (%) as of Sep 30, 2024

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund’s current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.25%.
 

Calendar Year Returns (%)

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fund at NAV 10.96 -1.08 9.56 14.80 -6.83 29.79 2.28 24.29 -2.78 7.92
Russell 1000® Value Index1 13.45 -3.83 17.34 13.66 -8.27 26.54 2.80 25.16 -7.54 11.46
 

Fund Facts

Class A Inception 09/23/1931
Expense Ratio2 1.03%
Distribution Frequency Quarterly

Risk Measures (3 Year)6 as of Nov 30, 2024

Alpha (%) 0.55
Beta 0.94
R-Squared (%) 95.69
Standard Deviation (%) 15.89
Sharpe Ratio 0.41
 

Morningstar Rating™ as of Nov 30, 2024

Time Period Rating Funds in
Large Value
Category
Overall 1093
3 Years 1093
5 Years 1029
10 Years 807
The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds and exchange-traded funds) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star.

The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Star ratings do not reflect the effect of any applicable sales load. Hollow stars denote Morningstar Extended Performance Ratings and are considered estimates based on the performance of the fund's oldest share class, adjusted for fees and expenses.

©2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
 

NAV History

Date NAV NAV Change
Dec 13, 2024 $26.24 -$0.09
Dec 12, 2024 $26.33 -$0.13
Dec 11, 2024 $26.46 -$0.02
Dec 10, 2024 $26.48 -$0.98
Dec 09, 2024 $27.46 -$0.08
Dec 06, 2024 $27.54 -$0.13
Dec 05, 2024 $27.67 -$0.10
Dec 04, 2024 $27.77 -$0.06
Dec 03, 2024 $27.83 -$0.13
Dec 02, 2024 $27.96 -$0.13
 

Distribution History7

Ex-Date Distribution Reinvest NAV
Dec 10, 2024 $0.05800 $26.48
Sep 10, 2024 $0.06220 $25.55
Jun 11, 2024 $0.08700 $25.23
Mar 11, 2024 $0.04840 $24.76
Dec 11, 2023 $0.05370 $22.67
Sep 11, 2023 $0.05750 $23.04
Jun 09, 2023 $0.06000 $22.51
Mar 09, 2023 $0.06000 $22.20
Dec 09, 2022 $0.07300 $22.79
Sep 09, 2022 $0.06000 $23.38
View All
No records in this table indicates that there has not been a distribution greater than .0001 within the past 3 years.
Fund prospectus
 

Capital Gain History7

Ex-Date Short-Term Long-Term Reinvest NAV
Dec 10, 2024 $0.81430 $26.48
Dec 11, 2023 $0.46350 $22.67
Dec 09, 2022 $0.71300 $22.79
No records in this table indicates that there has not been a capital gain greater than .0001 within the past 3 years.
Fund prospectus

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.

RISK CONSIDERATIONS 

The value of investments held by the Fund may increase or decrease in response to economic, and financial events (whether real, expected or perceived) in the U.S. and global markets. The value of equity securities is sensitive to stock market volatility. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical, currency exchange rates or other conditions. The Fund is exposed to liquidity risk when trading volume, lack of a market maker or trading partner, large position size, market conditions, or legal restrictions impair its ability to sell particular investments or to sell them at advantageous market prices. The impact of the coronavirus on global markets could last for an extended period and could adversely affect the Fund’s performance. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.

See the Fund's prospectus for information related to a primary benchmark index selected (if applicable) to comply with a regulation that requires the Fund's primary benchmark to represent the overall applicable market.


Portfolio

Asset Mix (%)4,8 as of Sep 30, 2024

Portfolio Statistics as of Sep 30, 2024

Average Market Cap $124.5B
Price/Earnings Ratio 19.31
Number of Holdings 61
Price/Book Ratio 3.02
Active Share9 83.58%
 

GICS Sector Breakdown (%)4 as of Sep 30, 2024

 

Fund Holdings (%)4,10 as of Oct 31, 2024

Holding % of Net Assets
Bristol-Myers Squibb Co 2.77%
Wells Fargo & Co 2.76%
AbbVie Inc 2.75%
American International Group Inc 2.65%
UnitedHealth Group Inc 2.63%
Charles Schwab Corp 2.56%
NextEra Energy Inc 2.42%
Micron Technology Inc 2.41%
Reinsurance Group of America Inc 2.39%
Cisco Systems Inc 2.33%
View All

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.

RISK CONSIDERATIONS 

The value of investments held by the Fund may increase or decrease in response to economic, and financial events (whether real, expected or perceived) in the U.S. and global markets. The value of equity securities is sensitive to stock market volatility. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical, currency exchange rates or other conditions. The Fund is exposed to liquidity risk when trading volume, lack of a market maker or trading partner, large position size, market conditions, or legal restrictions impair its ability to sell particular investments or to sell them at advantageous market prices. The impact of the coronavirus on global markets could last for an extended period and could adversely affect the Fund’s performance. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.

See the Fund's prospectus for information related to a primary benchmark index selected (if applicable) to comply with a regulation that requires the Fund's primary benchmark to represent the overall applicable market.


Management

Aaron Dunn, CFA

Aaron Dunn, CFA

Managing Director, Co-Head of Value Equity
Joined Eaton Vance 2012

Biography

Aaron is a managing director of Morgan Stanley. He is Co-Head of Value Equity and a portfolio manager on the Eaton Vance Value team. He is responsible for buy and sell decisions, portfolio construction and risk management. He is a member of the Eaton Vance Equity Strategy Committee. He joined Eaton Vance in 2012. Morgan Stanley acquired Eaton Vance in March 2021.

Aaron began his career in the investment management industry in 1999. Before joining Eaton Vance, Aaron was a senior equity analyst for Amundi Pioneer. He was previously affiliated with Invesco.

Aaron earned a B.S. from the University of Arkansas and an MBA from The University of Texas at Austin McCombs School of Business. He is a member of CFA Society Boston and a CFA charterholder.

Education
  • B.S. University of Arkansas
  • M.B.A. University of Texas at Austin

Experience
  • Managed Fund since 2017

 
Brad Galko, CFA

Brad Galko, CFA

Managing Director, Co-Head of Value Equity
Joined Eaton Vance 2013

Biography

Brad is a managing director of Morgan Stanley. He is Co-Head of Value Equity and a portfolio manager on the Eaton Vance Value team. He is responsible for buy and sell decisions, portfolio construction and risk management. He is a member of the Eaton Vance Equity Strategy Committee. He joined Eaton Vance in 2013. Morgan Stanley acquired Eaton Vance in March 2021.

Brad began his career in the investment management industry in 1991. Before joining Eaton Vance, Brad was a vice president and senior equity analyst at Amundi Pioneer. Previously, he was a vice president and senior equity research analyst at Morgan Stanley & Co.

Brad earned a B.B.A., magna cum laude, from the University of Notre Dame. He is a CFA charterholder and member of CFA Society Boston.

Education
  • B.B.A University of Notre Dame

Experience
  • Managed Fund since 2020

 

Literature

Literature

Fact Sheet

Download Fact Sheet - Last updated: Sep 30, 2024

Annual Financial Statements and Add'l Information

Download Annual Financial Statements and Add'l Information

Semi-Annual Financial Statements and Add'l Information

Download Semi-Annual Financial Statements and Add'l Information

Commentary

Download Commentary - Last updated: Sep 30, 2024

Attribution

Download Attribution - Last updated: Sep 30, 2024

Annual Report

Download Annual Report

Full Prospectus

Download Full Prospectus

Q1 Holdings

Download Q1 Holdings

Q3 Holdings

Download Q3 Holdings

Holdings - Form N-PORT

Download Holdings - Form N-PORT

Semi-Annual Report

Download Semi-Annual Report

Summary Prospectus

Download Summary Prospectus